Indian Pharma Should Give Up Their "Yogic" Ways To Win Global Markets
This article was originally published in The Pink Sheet Daily
Executive Summary
In order to gain a respectable rank on the global map, realignment of forces among Indian pharma is an imperative, Department Of Pharmaceuticals Joint Secretary Chaudhry exhorted Nov. 3 at the annual Pharma Summit organized by the Confederation of Indian Industry.
You may also be interested in...
Will The Next Teva Be From India? Global Scale, Product Mix, And A Strong Balance Sheet Can Trigger Big M&As By Indian Pharma
MUMBAI - News reports of Teva Pharmaceutical Industries Ltd. CEO Shlomo Yanai's recent visit to India sparked rumors that the company may have finally set its sights on the Indian market via a joint venture with Cipla Ltd. But even as the world's largest generic company toys with the idea of entering the sub-continent, leading analysts predict that the next Teva - referencing its multi-fold growth in the last six years - could soon emerge out of India
Merck Establishes JV With India's Sun Pharma To Develop Novel Combinations Of Branded Generics For Emerging Markets
MUMBAI - Merck & Co. is establishing a joint venture with India's Sun Pharmaceutical Industries Ltd. for a broad-based alliance to develop, manufacture and commercialize novel combinations and "incrementally innovative" branded generics in emerging markets, the two companies announced April 11
Cadila Heathcare Chairman Pankaj Patel On Consolidation In The Indian Industry And Why It's Not Happening Locally: An Interview With PharmAsia News
Pankaj Patel, chairman and managing director of India's fifth-largest firm Cadila Healthcare expresses an unswerving support for growth through partnerships. Riding on an early partnership with Swiss firm Nycomed and lucrative opportunities in niche segments like vaccines, Cadila's growth has been extraordinary - 18-fold growth in the last 15 years.